Reaffirming the preemptive authority of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and the Public Health Service Act (42 U.S.C. 201 et seq.) (including regulations thereunder) with respect to State laws that inhibit access to or use of any reproductive health product.
TQL analysis
Not yet gradedThis bill has no published Quiet Ledger grade yet.
Legislative structure
Criterion breakdown8 criteria · max 90
No grade to break down.Actions (6)
| Date | Time | Action |
|---|---|---|
| 2022-10-14 | — | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2022-10-14 | — | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2022-10-14 | — | Introduced in House |
| 2022-10-14 | — | Introduced in House |
| 2022-12-21 | 23:30:10 | Pursuant to the provisions of H. Res. 1529, H. Res. 1434 is considered passed House. |
| 2022-12-21 | 23:30:10 | Passed/agreed to in House: Pursuant to the provisions of H. Res. 1529, H. Res. 1434 is considered passed House. |
The Quiet Ledger grades legislation on its content. A bill grade is analysis of the bill — not a grade of its sponsor or of any member who voted on it.